Molecule profile · Module 4
Sermorelin — evidence and research limits
This label describes the research context of this profile, not a product-by-product approval determination. It does not mean every use of the molecule lacks approval. Read the existing evidence details and regulatory context for the specific preparation, indication and jurisdiction; no new approval is inferred.
MOLECULE PROFILE
- Evidence summary
- Investigational — profile context
- GHRH physiology explains a possible hormonal response. The cited long-acting CJC-1295 study and general growth-hormone evidence are contextual sources, not direct tests of sermorelin schedules for sleep, strength, body composition, or longevity. A product-specific clinical claim needs a study of that intervention and outcome. The interpretation is specific to the studied molecule, formulation, route, population, and endpoint. Reported commercial regimens are not validated by a study of a different product or outcome.
- Regulatory status varies by jurisdiction
- The academic source does not establish a current authorization for every preparation sold under this name. Product identity, formulation, indication, jurisdiction, and current official labeling must be checked separately. A discussion of compounding or an advisory meeting is not a product approval.
Educational information for healthcare professionals and the general public. Not individual medical advice, diagnosis, treatment, or a recommendation to use a compound.
Identity and mechanism
Sermorelin is discussed in the context of growth hormone-releasing hormone receptor signaling and pituitary responsiveness. Stimulation of the axis is a physiological response, not a direct measure of better sleep, greater strength, or longer life. Results from a different GHRH analogue or from growth hormone itself cannot establish the same effects for sermorelin.
What the evidence supports
GHRH physiology explains a possible hormonal response. The cited long-acting CJC-1295 study and general growth-hormone evidence are contextual sources, not direct tests of sermorelin schedules for sleep, strength, body composition, or longevity. A product-specific clinical claim needs a study of that intervention and outcome.
The interpretation is specific to the studied molecule, formulation, route, population, and endpoint. Reported commercial regimens are not validated by a study of a different product or outcome.
Regulatory context
The academic source does not establish a current authorization for every preparation sold under this name. Product identity, formulation, indication, jurisdiction, and current official labeling must be checked separately. A discussion of compounding or an advisory meeting is not a product approval.
Safety and uncertainty
Feedback mechanisms do not guarantee absolute safety. Do not adopt self-regulatory marketing claims as clinical evidence. Human safety cannot be inferred from a cell result, a product name, or lack of events in a small report. These educational adaptations do not provide an administration protocol.
Sport and anti-doping status
The WADA 2026 Prohibited List names sermorelin among growth hormone-releasing hormone analogues in section S2.2.4, prohibited at all times (in and out of competition). This is an anti-doping classification, separate from clinical evidence, product quality and regulatory approval. Medical supervision, a prescription or an approved indication does not by itself permit use in sport; any exemption for a documented medical condition is a separate decision by the competent anti-doping organization. The List is revised each year, so check the List in force on the relevant date.
Continue learning
Explore Module 4 in PEPTIDE Academy for the full evidence discussion.
References
Bibliographic sources shown for transparency. Citation verification pending; no citation is marked verified.
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. DOI: 10.1210/jc.2005-1536. PMID: 16352683.DOI 10.1210/jc.2005-1536 · PMID 16352683
- Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146(2):104-15. DOI: 10.7326/0003-4819-146-2-200701160-00005. PMID: 17227934.DOI 10.7326/0003-4819-146-2-200701160-00005 · PMID 17227934
- World Anti-Doping Agency. International Standard: Prohibited List 2026 (in effect from 1 January 2026). Checked 19 October 2026.
Related resources
Molecule profile · Module 4
CJC-1295 without DAC
Products described as CJC-1295 without DAC are discussed in relation to growth hormone-releasing hormone signaling. The name needs special scrutiny: a modified growth hormone-releasing factor sold without DAC cannot be treated as the same intervention as the long-acting CJC-1295 investigated in the cited human study. Molecular characterization precedes any comparison of exposure or hormone response.
Molecule profile · Module 4
Ipamorelin
Ipamorelin is investigated as an agonist of the ghrelin receptor, a target involved in growth hormone release and gastrointestinal physiology. The cited postoperative-ileus study addresses a specific surgical setting. A receptor mechanism or a measured hormone response does not establish improved strength, sleep, body composition, or the performance of a combination product.
Molecule profile · Module 4
Tesamorelin
Tesamorelin acts in the growth hormone-releasing hormone pathway. Its main clinical evidence in the course concerns adults with HIV-associated lipodystrophy and excess abdominal fat. A reduction in a specific visceral-fat compartment is not the same endpoint as general weight reduction, athletic performance, or reversal of aging.